The review found no eligible studies for this question.
Clobazam may leads to higher retention at 6 months (measured by the number of treatment failures… compared with phenytoin (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).
Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of individuals withdrawing from treatment compared with risperidone and previous ASM only (low certainty).
Gabapentin probably leads to higher reduction in seizure frequency of ≥ 50%: primary analysisNumber of… compared with placebo (moderate certainty).
Gabapentin may leads to higher adverse effects: ataxiaNumber of participants experiencing ataxia compared with placebo (low certainty).
Gabapentin probably leads to higher adverse effects: dizzinessNumber of participants experiencing… compared with placebo (moderate certainty).
Gabapentin may leads to higher adverse effects: fatigueNumber of participants experiencing fatigue compared with placebo (low certainty).
Gabapentin probably leads to lower adverse effects: nauseaNumber of participants experiencing nausea compared with placebo (moderate certainty).
Gabapentin probably leads to higher adverse effects: somnolenceNumber of participants experiencing… compared with placebo (moderate certainty).
Gabapentin probably leads to lower adverse effects: headacheNumber of participants experiencing headache compared with placebo (moderate certainty).
Intermittent oral or rectal diazepam probably leads to lower recurrent seizure at 6 months compared with placebo or no treatment (moderate certainty).
Continuous phenobarbital showed no clear difference in recurrent seizure at 18 months compared with placebo or no treatment (moderate certainty).
Continuous phenobarbital probably leads to lower recurrent seizure at 24 months compared with placebo or no treatment (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether continuous phenobarbital changes recurrent seizure at 60 months or greater compared with placebo or no treatment (very low certainty).